Sandoz

Companies Sandoz

News Sandoz

• Developing Countries and Generic Drug Firms Shaking Up the Pharma Industry

  Constricted budgets, the ‘patent cliff’ and the rise of emerging economies are forcing pharmaceutical companies to seriously reassess business strategies, finds a new report by healthcare industry analyst firm GlobalData. According to GlobalData’s 2012 Pharmaceutical Benchmark Report, the major phar more

• analytica: Diverse range of information in related-events program

  Some 1,000 exhibitors from the laboratory-technology, analysis and biotechnology sectors will present their latest products at analytica in Munich from April 17 – 20. Besides the exhibition and the scientific analytica Conference, a practice-oriented program of related events awaits visitors. There more

• Sandoz initiates two more Phase III biosimilar trials

  Sandoz announced that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®).The filgrastim study is to evaluate the efficacy and safety of Sandoz's more

Publications Sandoz

• Benzathine penicillin G: a model for long‐term pharmacokinetic comparison of parenteral long‐acting formulations

  Summary What is known and Objective:  Long‐acting intramuscular penicillin G injection is an important product for the management of some severe infections. However, testing the bioequivalence of such long‐acting formulations is difficult. Our aim was to undertake such a test using a generic for more

Market studies Sandoz

• Poland Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: Despite numerous challenges, we continue to believe Poland is the most attractive pharmaceutical market in Central and Eastern Europe (CEE). While the long-awaited Drug Reimbursement Act introduced in Q112 faced fierce opposition from the public and members of the healthcare profession, an more

• Switzerland Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: The period 2011-16 is forecast to witness the proliferation of government initiatives supporting the growth of Switzerland's generic medicines market, which will increasingly attract prominent international players in the field, as well as prompt local companies to get more involved in th more

• Slovenia Pharmaceuticals and Healthcare Report Q4 2012

  BMI View: Our view that Slovenia's drug market is one of the most stable in the region remains in place despite the fact that at the start of 2012, the government introduced new measures to control public drug expenditure. The Health Insurance Institute of Slovenia's savings target for the first yea more

Websites Sandoz